Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

Conditions:   Hepatocellular Carcinoma;   Liver Cancer, Adult;   Liver Cell Carcinoma Interventions:   Biological: LioCyx-M;   Drug: Lenvatinib Sponsor:   Lion TCR Pte. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials